Zhitong Financial App News, Shiyao Group (01093.HK) announced that the results of the Phase I/II clinical study of SYS6043, a novel B7 homologue 3 (ADC) targeting antibody conjugate drug (ADC) developed independently by the Group for advanced breast cancer patients (this study) were announced in the form of a quick oral report on October 26, 2026 at the 2026 European Society of Medical Oncology (ESMO) annual meeting (ID: 5RO). B7-H3 The study was reported by Professor Wang Hongxia of the Cancer Hospital Affiliated to Fudan University.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.